Salk’s Evans receives $2.5 million SU2C grant for pancreatic cancer clinical trial

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Salk professor and Howard Hughes Medical Institute investigator Ronald Evans was awarded $2.5 million by Stand Up to Cancer as part of a multi-institution team to conduct clinical studies to open up a new avenue for immunotherapy in the treatment of pancreatic cancer.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe

YOU MAY BE INTERESTED IN

How’s this for a paradox: The better cancer centers become at keeping patients alive, the more expensive cancer care becomes. This brutal tradeoff hits harder in rural areas, where the cancer burden is higher and the investigator and clinical trial representation is lower.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login